Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Arena Pharmaceuticals (ARNA)

89.89   -0.06 (-0.07%) 01-25 23:38
Open: 90.07 Pre. Close: 89.95
High: 90.35 Low: 89.045
Volume: 918,806 Market Cap: 5,534M
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with Second Genome, Inc.; United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; Eisai Inc.; and Aristea Therapeutics, Inc. for the development of RIST4721 for treatment of serious immune-mediated inflammatory diseases. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 90.94 - 91.813 91.813 - 92.34
Low: 87.159 - 88.316 88.316 - 89.016
Close: 88.566 - 90.446 90.446 - 91.583

Technical analysis

as of: 2022-01-25 4:22:13 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 107.75     One year: 110.06
Support: Support1: 89.04    Support2: 74.09
Resistance: Resistance1: 92.25    Resistance2: 94.23
Pivot: 92.16
Moving Average: MA(5): 90.57     MA(20): 92.35
MA(100): 68.89     MA(250): 67.45
MACD: MACD(12,26): 2.89     Signal(9): 4.39
Stochastic oscillator: %K(14,3): 9.37     %D(3): 5.35
RSI: RSI(14): 58.54
52-week: High: 94.23  Low: 45.50  Change(%): 21.1
Average Vol(K): 3-Month: 1370  10-Days: 1546

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
ARNA has closed above bottom band by 4.9%. Bollinger Bands are 67.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to Arena Pharmaceuticals's normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 25 Jan 2022
Arena Pharmaceuticals, Inc. (ARNA) Stock Falls -2.30% This Week: Is It a Good Pick? - InvestorsObserver

Sat, 22 Jan 2022
3 Clinical Trials to Watch in the First Half of 2022 - Nasdaq

Fri, 21 Jan 2022
Noteworthy ETF Inflows: XBI, ARNA, BCRX, BHVN - Nasdaq

Tue, 18 Jan 2022
SHAREHOLDER ALERT: WeissLaw LLP Reminds APR, ZNGA, BRG, and ARNA Shareholders About Its Ongoing Investigations - PRNewswire

Wed, 05 Jan 2022
Halper Sadeh LLP Investigates STXB, GCP, ARNA, JUPW; Shareholders are Encouraged to Contact the Firm - Be - Benzinga

Tue, 04 Jan 2022
Arena Pharmaceuticals INVESTOR -

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 62
Shares Float (M) 58
% Held by Insiders 0.55
% Held by Institutions 93.33
Shares Short (K) 1,530
Shares Short P. Month (K) 1,870

Stock Financials

EPS -9.720
EPS Est This Year -2.940
EPS Est Next Year -2.730
Book Value (p.s.) 13.070
Profit Margin
Operating Margin -1449108.13
Return on Assets (ttm) -30.8
Return on Equity (ttm) -59.2
Qtrly Rev. Growth
Gross Profit (p.s.) -5.254
Sales Per Share 0.001
EBITDA (p.s.) -8.647
Qtrly Earnings Growth
Operating Cash Flow (M) -438
Levered Free Cash Flow (M) -246

Stock Valuations

PE Ratio -9.25
PEG Ratio
Price to Book value 6.88
Price to Sales 149557.53
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date 2017-06-18
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.